Cargando…
Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology
Ventricular arrhythmia (VA) in autoimmune rheumatic diseases (ARD) is an expression of autoimmune inflammatory cardiomyopathy (AIC), caused by structural, electrical, or inflammatory heart disease, and has a serious impact on a patient’s outcome. Myocardial scar of ischemic or nonischemic origin thr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963646/ https://www.ncbi.nlm.nih.gov/pubmed/31835542 http://dx.doi.org/10.3390/diagnostics9040217 |
_version_ | 1783488329513172992 |
---|---|
author | Mavrogeni, Sophie I. Markousis-Mavrogenis, George Aggeli, Constantina Tousoulis, Dimitris Kitas, George D. Kolovou, Genovefa Iliodromitis, Efstathios K. Sfikakis, Petros P. |
author_facet | Mavrogeni, Sophie I. Markousis-Mavrogenis, George Aggeli, Constantina Tousoulis, Dimitris Kitas, George D. Kolovou, Genovefa Iliodromitis, Efstathios K. Sfikakis, Petros P. |
author_sort | Mavrogeni, Sophie I. |
collection | PubMed |
description | Ventricular arrhythmia (VA) in autoimmune rheumatic diseases (ARD) is an expression of autoimmune inflammatory cardiomyopathy (AIC), caused by structural, electrical, or inflammatory heart disease, and has a serious impact on a patient’s outcome. Myocardial scar of ischemic or nonischemic origin through a re-entry mechanism facilitates the development of VA. Additionally, autoimmune myocardial inflammation, either isolated or as a part of the generalized inflammatory process, also facilitates the development of VA through arrhythmogenic autoantibodies and inflammatory channelopathies. The clinical presentation of AIC varies from oligo-asymptomatic presentation to severe VA and sudden cardiac death (SCD). Both positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) can diagnose AIC early and be useful tools for the assessment of therapies during follow-ups. The AIC treatment should be focused on the following: (1) early initiation of cardiac medication, including ACE-inhibitors, b-blockers, and aldosterone antagonists; (2) early initiation of antirheumatic medication, depending on the underlying disease; and (3) potentially implantable cardioverter–defibrillator (ICD) and/or ablation therapy in patients who are at high risk for SCD. |
format | Online Article Text |
id | pubmed-6963646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69636462020-01-27 Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology Mavrogeni, Sophie I. Markousis-Mavrogenis, George Aggeli, Constantina Tousoulis, Dimitris Kitas, George D. Kolovou, Genovefa Iliodromitis, Efstathios K. Sfikakis, Petros P. Diagnostics (Basel) Review Ventricular arrhythmia (VA) in autoimmune rheumatic diseases (ARD) is an expression of autoimmune inflammatory cardiomyopathy (AIC), caused by structural, electrical, or inflammatory heart disease, and has a serious impact on a patient’s outcome. Myocardial scar of ischemic or nonischemic origin through a re-entry mechanism facilitates the development of VA. Additionally, autoimmune myocardial inflammation, either isolated or as a part of the generalized inflammatory process, also facilitates the development of VA through arrhythmogenic autoantibodies and inflammatory channelopathies. The clinical presentation of AIC varies from oligo-asymptomatic presentation to severe VA and sudden cardiac death (SCD). Both positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) can diagnose AIC early and be useful tools for the assessment of therapies during follow-ups. The AIC treatment should be focused on the following: (1) early initiation of cardiac medication, including ACE-inhibitors, b-blockers, and aldosterone antagonists; (2) early initiation of antirheumatic medication, depending on the underlying disease; and (3) potentially implantable cardioverter–defibrillator (ICD) and/or ablation therapy in patients who are at high risk for SCD. MDPI 2019-12-10 /pmc/articles/PMC6963646/ /pubmed/31835542 http://dx.doi.org/10.3390/diagnostics9040217 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mavrogeni, Sophie I. Markousis-Mavrogenis, George Aggeli, Constantina Tousoulis, Dimitris Kitas, George D. Kolovou, Genovefa Iliodromitis, Efstathios K. Sfikakis, Petros P. Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title | Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title_full | Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title_fullStr | Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title_full_unstemmed | Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title_short | Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology |
title_sort | arrhythmogenic inflammatory cardiomyopathy in autoimmune rheumatic diseases: a challenge for cardio-rheumatology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963646/ https://www.ncbi.nlm.nih.gov/pubmed/31835542 http://dx.doi.org/10.3390/diagnostics9040217 |
work_keys_str_mv | AT mavrogenisophiei arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT markousismavrogenisgeorge arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT aggeliconstantina arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT tousoulisdimitris arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT kitasgeorged arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT kolovougenovefa arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT iliodromitisefstathiosk arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology AT sfikakispetrosp arrhythmogenicinflammatorycardiomyopathyinautoimmunerheumaticdiseasesachallengeforcardiorheumatology |